94-5087. Prospective Grant of Exclusive Patent License

[Federal Register Volume 59, Number 44 (Monday, March 7, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-5087]


[[Page Unknown]]

[Federal Register: March 7, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

 

Prospective Grant of Exclusive Patent License

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license in a limited field of use to practice the 
inventions embodied in U.S. Patent 5,262,359 (formerly U.S. Patent 
Application 07/611,088), entitled ``Method of Propagating Human 
Paramyxoviruses Using Continuous Cell Lines'' to Baxter Diagnostics 
Inc.--Bartels Division having a place of business at Bellevue, 
Washington. The patent rights in these inventions have been assigned to 
the United States of America.
    The prospective exclusive license will be for the field of reagents 
for in vitro diagnostics. It will be royalty-bearing and will comply 
with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The 
prospective exclusive license may be granted unless, within sixty days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    These inventions relate to cell lines (NCI-H292) useful for 
propagating difficult to grow viruses such as parainfluenza and mumps. 
The availability of U.S. Patent Application 07/611,088 for licensing 
was published in the April 3, 1991 edition of the Federal Register.

ADDRESSES: Requests for a copy of the above identified patent, 
inquiries, comments and other materials relating to the contemplated 
license should be directed to: Mr. Mark Hankins, J.D., Office of 
Technology Transfer, National Institutes of Health, Box OTT, Bethesda, 
Maryland 20892 (telephone: [phone]; FAX: [phone]). 
Properly filed competing applications for a license filed in response 
to this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by the NIH Office of Technology Transfer 
within sixty (60) days of this notice will be considered.

    Dated: February 18, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-5087 Filed 3-4-94; 8:45 am]
BILLING CODE 4140-01-M